Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18317545 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9ANPC1ALOX15CHRM2 | |
| SCHEMBL18317379 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9ANPC1ALOX15CHRM2 | |
| SCHEMBL18317155 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9ANPC1ALOX15CHRM2 | |
| SCHEMBL18317157 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9ANPC1ALOX15CHRM2 | |
| SCHEMBL18317386 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9ANPC1ALOX15CHRM2 | |
| SCHEMBL18317563 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9ANPC1ALOX15CHRM2 | |
| SCHEMBL18318217 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9ANPC1ALOX15CHRM2 | |
| SCHEMBL18317195 | 0.98 | SMN1; SMN2 (0.67) | SMN1; SMN2RAB9ANPC1ALOX15CHRM2 | |
| SCHEMBL18317201 | 0.95 | SMN1; SMN2 (0.67) | SMN1; SMN2RAB9ANPC1ALOX15P2RX7 | |
| SCHEMBL21065524 | 0.90 | SMN1; SMN2 (0.79) | SMN1; SMN2RAB9ANPC1ALOX15P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016209785-A1 | UREA GELLANTS | THE PROCTER & GAMBLE COMPANY (US) | 2016-12-29 | — | — | WO | claimed |
| EP-3109233-A1 | UREA GELLANTS | The Procter and Gamble Company (US) | 2016-12-28 | — | — | EP | claimed |
| US-20160369208-A1 | UREA GELLANT | THE PROCTER & GAMBLE COMPANY | 2016-12-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160369208-A1 | UREA GELLANT | UGP2, UGGT1, SLC14A1 | SMN1; SMN2 4419/4885RAB9A 2575/4885NPC1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.